does cigna cover glp-1 for pcos PCOS: Is It the Right Choice? Therapeutic Potential of Glucagon-like Peptide-1
Description
In one Phase 2 trial, the drug, called elecoglipron, led patients with obesity to lose 11.2% of their weight after 36 weeks
Forrs: Getty images 2
Mopelola Adeyemo
22 , 5661, e10 (2010)
This is not semaglutide damages the retina so much as fast improvement can transiently worsen retinopathy in higher risk patients, which has parallels in insulin intensification
